Scinai Immunotherapeutics Ltd.
SCNI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3 | $2 | $6 | $24 |
| - Cash | $2 | $5 | $14 | $17 |
| + Debt | $2 | $21 | $22 | $29 |
| Enterprise Value | $3 | $18 | $13 | $36 |
| Revenue | $1 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$1 | -$1 | -$1 | -$1 |
| % Margin | -88.1% | – | – | – |
| EBITDA | -$7 | -$9 | -$10 | -$10 |
| % Margin | -1,062.2% | – | – | – |
| Net Income | $5 | -$7 | -$6 | -$8 |
| % Margin | 728.9% | – | – | – |
| EPS Diluted | 6 | -16.8 | -30.8 | -80 |
| % Growth | 135.7% | 45.5% | 61.5% | – |
| Operating Cash Flow | -$6 | -$9 | -$7 | -$7 |
| Capital Expenditures | -$0 | -$1 | -$1 | -$0 |
| Free Cash Flow | -$6 | -$10 | -$8 | -$8 |